Patents by Inventor Michael Tesar
Michael Tesar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11939395Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: June 9, 2021Date of Patent: March 26, 2024Assignee: Morphosys AGInventors: Michael Tesar, Ute Jäger
-
Publication number: 20230365709Abstract: The present invention relates to a trispecific antibody construct comprising (i.) a first binding domain (A), which is capable of specifically binding to a first target (A?) that is CD16A on the surface of an immune effector cell; (ii.) a second binding domain (B), which is capable of specifically binding to a second target (B?) that is another antigen on the surface of an immune effector cell, wherein said antigen is selected from the group comprising CD56, NKG2A, NKG2D, NKp30, NKp44, NKp46, NKp80, DNAM-1, SLAMF7, OX40, CD47/SIRP?, CD89, CD96, CD137, CD160, TIGIT, nectin-4, PD-1, PD-L1, LAG-3, CTLA-4, TIM-3, KIR2DL1-5, KIR3DL1-3, KIR2DS1-5 and CD3; and (iii.) a third binding domain (C), which is capable of specifically binding to a third target (C?) that is an antigen on the surface of a target cell. The present invention also relates to related nucleic acid molecules, vectors, host cells, methods of producing the antibody constructs, pharmaceutical compositions, medical uses, and kits.Type: ApplicationFiled: October 8, 2021Publication date: November 16, 2023Inventors: Thorsten ROSS, Joachim KOCH, Michael TESAR, Holger DULAT, Christian BREUNIG, Eike PETERS, Kristina ELLWANGER, Ivica FUCEK, Uwe REUSCH, Jens PAHL
-
Publication number: 20230190900Abstract: Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.Type: ApplicationFiled: October 19, 2022Publication date: June 22, 2023Inventors: Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Ellwanger, Uwe Reusch, Michael Damrat, Erich Rajkovic, Martin Treder
-
Patent number: 11510972Abstract: Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.Type: GrantFiled: September 2, 2020Date of Patent: November 29, 2022Assignee: AFFIMED GMBHInventors: Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Ellwanger, Uwe Reusch, Michael Damrat, Erich Rajkovic, Martin Treder
-
Publication number: 20210292431Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: ApplicationFiled: June 9, 2021Publication date: September 23, 2021Inventors: Michael TESAR, Ute JÄGER
-
Publication number: 20210253698Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: April 20, 2021Publication date: August 19, 2021Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Patent number: 11059902Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: September 7, 2018Date of Patent: July 13, 2021Assignee: MORPHOSYS AGInventors: Michael Tesar, Ute Jäger
-
Patent number: 11001633Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: GrantFiled: December 13, 2019Date of Patent: May 11, 2021Assignee: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Publication number: 20200405833Abstract: Described are tetravalent, bispecific EGFR/CD16A antigen-binding proteins for engaging NK-cells towards EGFR-positive cells. EGFR/CD16A antigen-binding proteins with different pharmacokinetic (PK) properties are described. Further described is the use of bispecific EGFR/CD16A antigen-binding proteins for the treatment of an EGFR-positive malignancy, such as EGFR-positive tumors.Type: ApplicationFiled: September 2, 2020Publication date: December 31, 2020Inventors: Michael Kluge, Michael Tesar, Ivica Fucek, Kristina Wanger, Uwe Reusch, Michael Damrat, Erich Rajkovic, Martin Treder
-
Patent number: 10640568Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: March 6, 2018Date of Patent: May 5, 2020Assignee: Pfizer Inc.Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Lawrence Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Publication number: 20200109202Abstract: The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (Fc?RIIIA)expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.Type: ApplicationFiled: December 13, 2019Publication date: April 9, 2020Applicant: Affimed GmbHInventors: Michael Tesar, Kristina Ellwanger, Ivica Fucek, Uwe Reusch, Thorsten Ross, Joachim Koch, Erich Rajkovic, Martin Treder
-
Publication number: 20190077877Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: ApplicationFiled: September 7, 2018Publication date: March 14, 2019Inventors: MICHAEL TESAR, UTE JAGER
-
Patent number: 10184005Abstract: The present invention provides novel antibodies and methods for using recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These methods take advantage of newly discovered antibodies and surprising properties of such antibodies, such as the ability to bind CD38 of minipig origin and the ability to induce, by cross-linking, specific killing of cells that express CD38. These antibodies as well as the novel methods for using those antibodies can be used to treat, for example, hematological malignancies such as multiple myeloma.Type: GrantFiled: October 8, 2015Date of Patent: January 22, 2019Assignee: MORPHOSYS AGInventors: Michael Tesar, Ute Jaeger
-
Publication number: 20180215832Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: ApplicationFiled: January 11, 2018Publication date: August 2, 2018Inventors: MICHAEL TESAR, UTE JAGER
-
Publication number: 20180194851Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: March 6, 2018Publication date: July 12, 2018Applicant: Pfizer Inc.Inventors: Bianca AHRENS, Sangita M. BAXI, Timothy Scott FISHER, Richard Michael JEROME, Kathrin LADETZKI-BAEHS, Theodore Lawrence OLIPHANT, Leslie Lynne SHARP, Michael TESAR, Libbey Anne YATES, Moritz ZULLEY
-
Publication number: 20180057601Abstract: The present disclosure relates to a novel humanized antibody capable of binding to ADAM17 and also the amino and nucleic acid sequences coding for said antibody. From one aspect, the disclosure relates to a novel humanized antibody, or antigen-binding fragments, capable of binding to ADAM17 with anti-tumour activities. The disclosure also comprises the use of said humanized antibody as a drug for the treatment of cancer. Finally, the invention comprises compositions comprising said humanized antibody, alone or in combination or conjugation with other anticancer compounds, and the use of same for the treatment of cancer.Type: ApplicationFiled: January 4, 2016Publication date: March 1, 2018Inventors: Peter LOWE, Sven BERGER, Michael TESAR
-
Patent number: 9873733Abstract: This disclosure generally relates to antibodies or fragments thereof which interact with the bacterial protein MprF. The disclosure further discloses antibodies, which bind to specific extracellular motifs of MprF. The disclosure further relates to therapeutics comprising MprF-specific antibodies and methods of treatment using MprF-specific antibodies or fragments thereof.Type: GrantFiled: December 20, 2013Date of Patent: January 23, 2018Assignees: MORPHOSYS AG., UNIVERSITAETSKLINIKUM TUEBINGENInventors: Christoph Michael Ernst, Andreas Paul Peschel, Alexandra Kraus, Michael Tesar
-
Patent number: 9758590Abstract: The present invention provides recombinant antigen-binding regions and antibodies and functional fragments containing such antigen-binding regions that are specific for CD38, which plays an integral role in various disorders or conditions. These antibodies, accordingly, can be used to treat, for example, hematological malignancies such as multiple myeloma. Antibodies of the invention also can be used in the diagnostics field, as well as for investigating the role of CD38 in the progression of disorders associated with malignancies. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. The invention also provides isolated novel epitopes of CD38 and methods of use therefore.Type: GrantFiled: December 4, 2015Date of Patent: September 12, 2017Assignee: MORPHOSYS AGInventors: Michael Tesar, Ute Jaeger
-
Publication number: 20160369000Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: ApplicationFiled: September 6, 2016Publication date: December 22, 2016Applicant: Pfizer Inc.Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Lawrence Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
-
Patent number: 9468678Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.Type: GrantFiled: May 13, 2014Date of Patent: October 18, 2016Assignee: Pfizer Inc.Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley